Alzheimer's Disease/Cognition News

Body composition patterns associated with weight and fat distribution were strongly correlated with neurodegenerative disease and brain aging, mediated by cardiovascular disease, according to research published in Neurology.

Annovis Bio Inc. has secured a U.S. patent for methods of treating acute traumatic brain injuries with its lead drug candidate, an oral, small molecule neurotoxic protein inhibitor.

Lantheus Holdings Inc. has announced the acquisition of Meilleur Technologies Inc., which includes the transfer of its rights to an amyloid-beta positron emission tomography imaging agent.

Semaglutide was not associated with increased risks for adverse neurologic or psychological disorders at 1 year compared with other diabetes drugs, according to data published in eClinicalMedicine.

The FDA has granted fast-track designation to a proprietary, scalable, allogeneic, investigational cellular therapy in development to address symptoms of mild Alzheimer’s disease, according to the manufacturer.

The FDA recently approved injectable Kisunla to treat early-stage Alzheimer’s disease, joining Leqembi, which gained FDA approval in July 2023 for the same purpose.

NYU Langone was again the top hospital in the United States for neurology and neurosurgery, according to the latest annual Best Hospitals Survey issued by U.S. News & World Report.

Persistent higher or moderate-to-increasing inflammation that begins in early adulthood may result in worsening midlife executive function and processing speed, according to data published in Neurology.

The FDA approved Kisunla for adults with early symptomatic Alzheimer’s disease, including those with mild cognitive impairment and mild dementia with confirmed amyloid pathology.

A self-administered assessment tool was effective in identifying cognitive impairment vs. routine care in primary care settings, according to results recently published in Frontiers in Medicine.